[Management of acute phase of autoimmune haemolytic anemia].
Pérel
Y
Y
Unité d'oncohématologie-pédiatrique, hôpital des enfants, Bordeaux, Paris, France.
Aladjidi
N
N
Jeanne
M
M
D000208:Acute Disease; D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D001323:Autoantibodies / Q000097:blood; D001787:Blood Group Incompatibility / Q000097:blood / Q000517:prevention & control; D002648:Child; D000075202:Contraindications; D003450:Cryoglobulins / Q000276:immunology; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D017707:Erythrocyte Transfusion; D005440:Fluid Therapy; D005500:Follow-Up Studies; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000097:blood; D007518:Isoantibodies / Q000097:blood; D008775:Methylprednisolone / Q000008:administration & dosage; D010102:Oxygen Inhalation Therapy; D010951:Plasma Exchange; D011239:Prednisolone / Q000008:administration & dosage; D015996:Survival Rate
D001323:Autoantibodies; D003450:Cryoglobulins; D007074:Immunoglobulin G; D007518:Isoantibodies; C029443:cold agglutinins; D011239:Prednisolone; D008775:Methylprednisolone